ArticlePharmaceuticals (Basel, Switzerland)2022

Adjuvant Anti-PD-1 Immunotherapy versus Conventional Therapy for Stage III Melanoma: A Real-World Retrospective Cohort Study.

Tong Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.